Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy

Oncology Letters

Volumn 1, Issue 4, 2010, Pages 641-647

  Yan, Hongjiang ^a   Wang, Renben ^a   Yu, Jinming ^a   Jiang, Shumei ^a   Zhu, Kunli ^a   Mu, Dianbin ^b   Xu, Zhongfa ^c  

^a Departments of Radiation Oncology   (China)

^b Departments of Pathology   (China)

^c SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Ki 67; Pre operative chemoradiotherapy; Rectal cancer; Second mitochondria derived activator of caspase; Vascular endothelial growth factor

Indexed keywords

FLUOROURACIL; FOLINIC ACID; KI 67 ANTIGEN; OXALIPLATIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROTEIN EXPRESSION; RECTUM CARCINOMA; RECTUM SURGERY; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 77954930591     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000113     Document Type: Article

References (35)

1. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl j med 351: 1731-1740, 2004.
2. Bosset JF, Calais G, Mineur L, et al: Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 23: 5620-5627, 2005.
3. Bosset JF, Collette L, Calais G, et al: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl j med 355: 1114-1123, 2006.
4. Gerard J, Romestaing P, Bonnetain F, et al: Preoperative chemo-radiotherapy (CT-RT) improves local control in T3-4 rectal cancers: results of the ffCD 9203 randomised trial. Int J Radiat Oncol biol Phys 63: 2-3, 2005.
5. Das P and Crane CH: Preoperative and adjuvant treatment of localized rectal cancer. Curr Oncol Rep 8: 167-173, 2006.
6. McLean CM and Duncan W: Rectal cancer: a review of randomized trials of adjuvant radiotherapy. Clin Oncol 7: 349-358, 1995.
7. Friedmann P, Garb JL, Park WC, et al: Pace OT survival following moderate-dose preoperative radiation therapy for carcinoma of the rectum. Cancer 55: 967-973, 1985.
8. Kerman HD, Roberson SH, Bloom TS, et al: Rectal carcinoma. Long-term experience with moderately high-dose preoperative radiation and low anterior resection. Cancer 69: 2813-2819, 1992.
9. Kim DW, Lim SB, Kim DY, et al: Pre-operative chemo-radio-therapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge. Eur j Surg Oncol 32: 162-167, 2006.
10. Minsky BD: Oxaliplatin-based combined-modality therapy for rectal cancer. Semin Oncol 30: 26-33, 2003.
11. Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c dependent caspase activation by elimination IAP inhibition. Cell 102: 33-42, 2000.
12. Kang S-M, Maeda K, Onoda N, et al: Combined analysis of p53 and vascular endothelial growth factor in CRC for determination of tumor vascularity and liver metastasis. Int j Cancer 74: 502-507, 1997.
13. Wong MP, Cheung N, Yuen ST, Leung SY and Chung LP: Vascular endothelial GF is up-regulated in the early pre-ma-lignant stage of colorectal tumor progression. Int j Cancer 81: 845-850, 1999.
14. Tonini T, Rossi F and Claudio PP: molecular basis of angiogen-esis and cancer. Oncogene 22: 6549-6556, 2003.
15. Lutsenko SV, Kiselev SM and Severin SE: Molecular mechanisms of tumor angiogenesis. Biochem 68: 286-300, 2003.
16. Ferrara N, Gerber H-P and LeCouter J: The biology of VEGF and its receptors. Nat med 9: 669-676, 2003.
17. Falm E: Angiogenesis inhibitors in clinical development; where are we now and where are we going? br J Cancer 90: 1-7, 2004.
18. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
19. Harmey JH and Bouchier-Hayes D: vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 24: 280-283, 2002.
20. Willett C, Boucher Y, Di Tomaso E, et al: Direct evidence that the veGf-specifc antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat med 10: 145-147, 2004.
21. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defned by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
22. Song Z, Yao X and Wu M: Direct interaction between survivin and Smac/DiAblO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J biol Chem 278: 23130-23140, 2003.
23. Roberts DL, Merrison W, Macfarlane M and Cohen GM: The inhibitor of apoptosis protein-binding domain of Smac is not essential for its proapoptotic activity. J Cell biol 153: 221-228, 2001.
24. Sekimura A, Konishi A, mizuno K, et al: Expression of Smac/ DiAblO is a novel prognostic marker in lung cancer. Oncol Rep 11: 797-802, 2004.
25. Zheng LD, Xiong ZF, Zhu JW and Wang ZH: effects of Smac gene over-expression on the radiotherapeutic sensitivities of cervical cancer cell line HeLa [j]. Chin med j 118: 226-230, 2005.
26. Jia L, Patwari Y, Kelsey SM, et al: Role of Smac in human leukaemic cell apoptosis and proliferation. Oncogene 22: 1589-1589, 2003.
27. Zlobec I, Steele R and Compton CC: VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 104: 2517-2521, 2005.
28. Giralt J, Navalpotro B, Hermosilla E, et al: Prognostic signifcance of vascular endothelial growth factor and cyclooxy-genase-2 in patients with rectal cancer treated with preoperative radiotherapy. Oncology 71: 312-319, 2006.
29. Kakeji Y, Koga T, Sumiyoshi Y, et al: Clinical signifcance of vascular endothelial growth factor expression in gastric cancer. j Exp Clin Cancer Res 21: 125-129, 2002.
30. Inoue Y, Ojima E, Watanabe H, et al: Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer? Oncol Rep 18: 369-375, 2007.
31. Rau B, Sturm I, Lage H, et al: Dynamic expression profle of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21: 3391-3401, 2003.
32. Kim NK, Park JK, Lee KY, et al: P53, bCL-2 and Ki-67 expression according to tumor response after concurrent chemo-radiotherapy for advanced rectal cancer. Ann Surg Oncol 8: 418-424, 2001.
33. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. j Cell Physiol 182: 311-322, 2000.
34. Adell G, Zhang H, Jansson A, Sun XF, Stål O and Nordenskjöld B: Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer Int j Radiat Oncol biol Phys 50: 659-663, 2001.
35. Debucquoy A, Goethals L, Geboes K, Roels S, Mc Bride WH and Haustermans K: molecular responses of rectal cancer to preoperative chemoradiation. Radiother Oncol 80: 172-177, 2006.